The iron deficiency anemia treatment market size has grown rapidly in recent years. It will grow from $8.83 billion in 2025 to $9.98 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to rising prevalence of iron deficiency disorders, increased diagnosis of anemia in chronic diseases, expansion of hospital-based treatment protocols, availability of oral iron supplements, growing awareness of anemia management.
The iron deficiency anemia treatment market size is expected to see rapid growth in the next few years. It will grow to $16.17 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing geriatric population susceptibility, rising demand for rapid iron repletion therapies, expansion of injectable iron usage, growing focus on patient-centric treatment models, advancements in iron formulation technologies. Major trends in the forecast period include increasing adoption of intravenous iron therapies, rising use of high-bioavailability iron formulations, growing focus on personalized anemia treatment approaches, expansion of outpatient and home-based iron therapy, improved patient monitoring and compliance tools.
The increasing prevalence of chronic kidney disease is expected to drive the growth of the iron deficiency anemia treatment market in the coming years. Chronic kidney disease (CKD) is characterized by the gradual decline in kidney function over time. The rise in CKD cases is largely associated with increasing rates of diabetes, as prolonged elevated blood glucose levels damage renal blood vessels and impair the kidneys’ ability to filter waste effectively. Iron deficiency anemia treatment plays an important role in managing CKD by improving oxygen delivery to tissues, reducing fatigue, and enhancing overall quality of life. In addition, addressing anemia caused by reduced erythropoietin production in CKD patients may contribute to improved kidney-related outcomes. For instance, in April 2024, according to a report published by AstraZeneca, a UK-based pharmaceutical company, it was projected that by 2032 up to 16.5% of the population across eight countries, including the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China, and Australia, would be affected by chronic kidney disease, with advanced-stage cases expected to increase by as much as 59.3%. Therefore, the rising incidence of chronic kidney disease is contributing to the growth of the iron deficiency anemia treatment market.
Major companies operating in the iron deficiency anemia treatment market are focusing on the development of next-generation treatment options, such as advanced iron injections, to improve efficacy, safety, and patient convenience. Iron injections represent new or significantly improved injectable iron therapies that offer meaningful advancements in the management of iron deficiency and iron deficiency anemia. For example, in March 2024, Cadila Pharmaceuticals, an India-based pharmaceutical company, launched Redshot FCM, an intravenous iron therapy formulated with ferric carboxymaltose for the treatment of iron deficiency anemia. The product features rapid iron replenishment, a low risk of anaphylaxis, high-dose single-infusion administration for faster correction, and suitability for both pediatric patients aged one year and above and adults. It supports quicker hemoglobin recovery and is designed for high-risk populations, including pregnant women and cancer patients, while offering improved tolerability.
In March 2025, Hyloris Pharmaceuticals, a Belgium-based specialty biopharmaceutical company, partnered with AFT Pharmaceuticals to co-develop HY 094, a novel injectable therapy for iron deficiency and iron deficiency anemia. Through this collaboration, the companies aim to advance the clinical development, manufacturing, and global commercialization of HY 094, with Hyloris leading activities in Europe and AFT focusing on markets outside Europe. This partnership reflects the iron deficiency anemia treatment market’s increasing emphasis on innovative injectable therapies and international collaboration to expand patient access. AFT Pharmaceuticals is a New Zealand-based pharmaceutical company.
Major companies operating in the iron deficiency anemia treatment market are Sanofi SA, Fresenius SE & Co. KGaA, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Pharmascience Inc., American Regent Inc., PharmaNutra S.p.A., Rockwell Medical Inc., Keryx Biopharmaceuticals Inc., Pharmacosmos A/S, AdvaCare Pharma USA LLC, Apotex Inc., Shield Therapeutics plc, CSL Vifor AG, Abbott Laboratories, Bayer AG, Pfizer Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd.
North America was the largest region in the iron deficiency anemia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the iron deficiency anemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the iron deficiency anemia treatment market by increasing costs of imported active pharmaceutical ingredients, injectable iron compounds, medical-grade excipients, and infusion equipment used in oral and intravenous therapies. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported pharmaceutical inputs, while Asia-Pacific faces cost pressures on generic drug manufacturing. These tariffs are contributing to higher treatment costs and procurement delays. However, they are also encouraging local drug manufacturing, regional API sourcing, and expanded domestic production of iron therapies, supporting long-term supply stability.
The iron deficiency anemia treatment market research report is one of a series of new reports that provides iron deficiency anemia treatment market statistics, including iron deficiency anemia treatment industry global market size, regional shares, competitors with a iron deficiency anemia treatment market share, detailed iron deficiency anemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency anemia treatment industry. This iron deficiency anemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Iron deficiency anemia treatment encompasses the medical strategies and interventions designed to correct iron deficiency in the body. These treatments aim to replenish iron levels through iron supplements, dietary changes, or intravenous iron, addressing the underlying cause of the deficiency and relieving associated symptoms.
The main types of iron deficiency anemia treatment include medications, blood transfusions, and other therapies. Medications refer to drugs or substances used to treat, prevent, or manage conditions including iron deficiency anemia. These include various types of iron supplements such as ferrous sulfate, ferrous gluconate, ferrous fumarate, ferric hydroxide, sodium ferric gluconate, and iron carbohydrates. These treatments are used across different therapy areas such as inflammatory bowel disease, renal disorders, obstetrics and gynecology, congestive heart failure, oncology, and more. The treatments can be administered orally or via injection and are utilized in various settings, including hospitals, clinics, home care environments, and pharmacies.
The iron deficiency anemia treatment market consists of revenues earned by entities by providing services such as dietary counseling, monitoring and follow-up care, customized treatment plans, and management of side effects. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron deficiency anemia treatment market also includes sales of iron-fortified foods, iron infusion kits, liquid iron supplements, and iron-rich multivitamins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The iron deficiency anemia treatment market size is expected to see rapid growth in the next few years. It will grow to $16.17 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing geriatric population susceptibility, rising demand for rapid iron repletion therapies, expansion of injectable iron usage, growing focus on patient-centric treatment models, advancements in iron formulation technologies. Major trends in the forecast period include increasing adoption of intravenous iron therapies, rising use of high-bioavailability iron formulations, growing focus on personalized anemia treatment approaches, expansion of outpatient and home-based iron therapy, improved patient monitoring and compliance tools.
The increasing prevalence of chronic kidney disease is expected to drive the growth of the iron deficiency anemia treatment market in the coming years. Chronic kidney disease (CKD) is characterized by the gradual decline in kidney function over time. The rise in CKD cases is largely associated with increasing rates of diabetes, as prolonged elevated blood glucose levels damage renal blood vessels and impair the kidneys’ ability to filter waste effectively. Iron deficiency anemia treatment plays an important role in managing CKD by improving oxygen delivery to tissues, reducing fatigue, and enhancing overall quality of life. In addition, addressing anemia caused by reduced erythropoietin production in CKD patients may contribute to improved kidney-related outcomes. For instance, in April 2024, according to a report published by AstraZeneca, a UK-based pharmaceutical company, it was projected that by 2032 up to 16.5% of the population across eight countries, including the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China, and Australia, would be affected by chronic kidney disease, with advanced-stage cases expected to increase by as much as 59.3%. Therefore, the rising incidence of chronic kidney disease is contributing to the growth of the iron deficiency anemia treatment market.
Major companies operating in the iron deficiency anemia treatment market are focusing on the development of next-generation treatment options, such as advanced iron injections, to improve efficacy, safety, and patient convenience. Iron injections represent new or significantly improved injectable iron therapies that offer meaningful advancements in the management of iron deficiency and iron deficiency anemia. For example, in March 2024, Cadila Pharmaceuticals, an India-based pharmaceutical company, launched Redshot FCM, an intravenous iron therapy formulated with ferric carboxymaltose for the treatment of iron deficiency anemia. The product features rapid iron replenishment, a low risk of anaphylaxis, high-dose single-infusion administration for faster correction, and suitability for both pediatric patients aged one year and above and adults. It supports quicker hemoglobin recovery and is designed for high-risk populations, including pregnant women and cancer patients, while offering improved tolerability.
In March 2025, Hyloris Pharmaceuticals, a Belgium-based specialty biopharmaceutical company, partnered with AFT Pharmaceuticals to co-develop HY 094, a novel injectable therapy for iron deficiency and iron deficiency anemia. Through this collaboration, the companies aim to advance the clinical development, manufacturing, and global commercialization of HY 094, with Hyloris leading activities in Europe and AFT focusing on markets outside Europe. This partnership reflects the iron deficiency anemia treatment market’s increasing emphasis on innovative injectable therapies and international collaboration to expand patient access. AFT Pharmaceuticals is a New Zealand-based pharmaceutical company.
Major companies operating in the iron deficiency anemia treatment market are Sanofi SA, Fresenius SE & Co. KGaA, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Pharmascience Inc., American Regent Inc., PharmaNutra S.p.A., Rockwell Medical Inc., Keryx Biopharmaceuticals Inc., Pharmacosmos A/S, AdvaCare Pharma USA LLC, Apotex Inc., Shield Therapeutics plc, CSL Vifor AG, Abbott Laboratories, Bayer AG, Pfizer Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd.
North America was the largest region in the iron deficiency anemia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the iron deficiency anemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the iron deficiency anemia treatment market by increasing costs of imported active pharmaceutical ingredients, injectable iron compounds, medical-grade excipients, and infusion equipment used in oral and intravenous therapies. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported pharmaceutical inputs, while Asia-Pacific faces cost pressures on generic drug manufacturing. These tariffs are contributing to higher treatment costs and procurement delays. However, they are also encouraging local drug manufacturing, regional API sourcing, and expanded domestic production of iron therapies, supporting long-term supply stability.
The iron deficiency anemia treatment market research report is one of a series of new reports that provides iron deficiency anemia treatment market statistics, including iron deficiency anemia treatment industry global market size, regional shares, competitors with a iron deficiency anemia treatment market share, detailed iron deficiency anemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency anemia treatment industry. This iron deficiency anemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Iron deficiency anemia treatment encompasses the medical strategies and interventions designed to correct iron deficiency in the body. These treatments aim to replenish iron levels through iron supplements, dietary changes, or intravenous iron, addressing the underlying cause of the deficiency and relieving associated symptoms.
The main types of iron deficiency anemia treatment include medications, blood transfusions, and other therapies. Medications refer to drugs or substances used to treat, prevent, or manage conditions including iron deficiency anemia. These include various types of iron supplements such as ferrous sulfate, ferrous gluconate, ferrous fumarate, ferric hydroxide, sodium ferric gluconate, and iron carbohydrates. These treatments are used across different therapy areas such as inflammatory bowel disease, renal disorders, obstetrics and gynecology, congestive heart failure, oncology, and more. The treatments can be administered orally or via injection and are utilized in various settings, including hospitals, clinics, home care environments, and pharmacies.
The iron deficiency anemia treatment market consists of revenues earned by entities by providing services such as dietary counseling, monitoring and follow-up care, customized treatment plans, and management of side effects. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron deficiency anemia treatment market also includes sales of iron-fortified foods, iron infusion kits, liquid iron supplements, and iron-rich multivitamins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Iron Deficiency Anemia Treatment Market Characteristics
3. Iron Deficiency Anemia Treatment Market Supply Chain Analysis
4. Global Iron Deficiency Anemia Treatment Market Trends and Strategies
5. Iron Deficiency Anemia Treatment Market Analysis of End Use Industries
7. Global Iron Deficiency Anemia Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Iron Deficiency Anemia Treatment Total Addressable Market (TAM) Analysis for the Market
9. Iron Deficiency Anemia Treatment Market Segmentation
10. Iron Deficiency Anemia Treatment Market Regional and Country Analysis
11. Asia-Pacific Iron Deficiency Anemia Treatment Market
12. China Iron Deficiency Anemia Treatment Market
13. India Iron Deficiency Anemia Treatment Market
14. Japan Iron Deficiency Anemia Treatment Market
15. Australia Iron Deficiency Anemia Treatment Market
16. Indonesia Iron Deficiency Anemia Treatment Market
17. South Korea Iron Deficiency Anemia Treatment Market
18. Taiwan Iron Deficiency Anemia Treatment Market
19. South East Asia Iron Deficiency Anemia Treatment Market
20. Western Europe Iron Deficiency Anemia Treatment Market
21. UK Iron Deficiency Anemia Treatment Market
22. Germany Iron Deficiency Anemia Treatment Market
23. France Iron Deficiency Anemia Treatment Market
24. Italy Iron Deficiency Anemia Treatment Market
25. Spain Iron Deficiency Anemia Treatment Market
26. Eastern Europe Iron Deficiency Anemia Treatment Market
27. Russia Iron Deficiency Anemia Treatment Market
28. North America Iron Deficiency Anemia Treatment Market
29. USA Iron Deficiency Anemia Treatment Market
30. Canada Iron Deficiency Anemia Treatment Market
31. South America Iron Deficiency Anemia Treatment Market
32. Brazil Iron Deficiency Anemia Treatment Market
33. Middle East Iron Deficiency Anemia Treatment Market
34. Africa Iron Deficiency Anemia Treatment Market
36. Iron Deficiency Anemia Treatment Market Competitive Landscape and Company Profiles
37. Iron Deficiency Anemia Treatment Market Other Major and Innovative Companies
40. Iron Deficiency Anemia Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Iron Deficiency Anemia Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses iron deficiency anemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for iron deficiency anemia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The iron deficiency anemia treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment Type: Medications; Blood Transfusions; Other Treatment Types2) By Drug Type: Ferrous Sulfate; Iron Carbohydrates; Other Drug Types
3) By Therapy Areas: Inflammatory Bowel Disease; Oncology; Other Therapy Areas
4) By Route Of Administration: Oral; Injectable
5) By End User: Hospitals; Clinics; Home Care Settings; Pharmacies
Subsegments:
1) By Medications: Oral Iron Supplements; Intravenous Iron Therapy; Iron-Based Injections; Erythropoiesis-Stimulating Agents2) By Blood Transfusions: Packed Red Blood Cells Transfusion; Whole Blood Transfusion
3) By Other Treatment Types: Dietary Modifications; Iron Infusion Therapy; Long-Term Maintenance Iron Therapy
Companies Mentioned: Sanofi SA; Fresenius SE & Co. KGaA; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz Group AG; Daiichi Sankyo Company Limited; Lupin Limited; Zydus Lifesciences Limited; Alkem Laboratories Ltd.; Pharmascience Inc.; American Regent Inc.; PharmaNutra S.p.A.; Rockwell Medical Inc.; Keryx Biopharmaceuticals Inc.; Pharmacosmos A/S; AdvaCare Pharma USA LLC; Apotex Inc.; Shield Therapeutics plc; CSL Vifor AG; Abbott Laboratories; Bayer AG; Pfizer Inc.; Cipla Limited; Dr. Reddy’s Laboratories Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Iron Deficiency Anemia Treatment market report include:- Sanofi SA
- Fresenius SE & Co. KGaA
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Sandoz Group AG
- Daiichi Sankyo Company Limited
- Lupin Limited
- Zydus Lifesciences Limited
- Alkem Laboratories Ltd.
- Pharmascience Inc.
- American Regent Inc.
- PharmaNutra S.p.A.
- Rockwell Medical Inc.
- Keryx Biopharmaceuticals Inc.
- Pharmacosmos A/S
- AdvaCare Pharma USA LLC
- Apotex Inc.
- Shield Therapeutics plc
- CSL Vifor AG
- Abbott Laboratories
- Bayer AG
- Pfizer Inc.
- Cipla Limited
- Dr. Reddy’s Laboratories Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 9.98 Billion |
| Forecasted Market Value ( USD | $ 16.17 Billion |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
